Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients

被引:1
作者
Junior, Gilberto de Castro [1 ]
Federico, Miriam Hatsue Honda [1 ]
机构
[1] Univ Sao Paulo, Fac Med, InRad Hosp Clin, Clin Oncol Serv, BR-05403001 Sao Paulo, Brazil
关键词
amifostine; head and neck cancer; radiation therapy; xerostomia;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review As part of the multidisciplinary approach to head and neck cancer patients, radiation therapy plays an essential role, improving locoregional control. Radiation therapy-induced xerostomia is a late side-effect that increases the risk for developing dental caries and compromises oral mucosal integrity, resulting in oral pain, loss of taste, difficulties with swallowing and chewing, sleep disorders and worse quality of life. This review focuses on evaluation, prevention and management of radiation therapy-induced xerostomia. Recent findings In terms of xerostomia prevention, some clinical trials evaluating amifostine and intensity-modulated radiation therapy have shown positive results. Pilocarpine is a useful agent as a treatment of radiation-induced xerostomia in head and neck cancer patients. Summary Despite some advances in radiation therapy-induced xerostomia prevention, its treatment is an area in which advances are urgently needed.
引用
收藏
页码:266 / 270
页数:5
相关论文
共 44 条
[1]   Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the SMART (simultaneous modulated accelerated radiation therapy) boost technique [J].
Amosson, CM ;
Teh, BS ;
Van, TJ ;
Uy, N ;
Huang, E ;
Mai, WY ;
Frolov, A ;
Woo, SY ;
Chiu, JK ;
Carpenter, LS ;
Lu, HH ;
Grant, WH ;
Butler, EB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01) :136-144
[2]   Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy [J].
Andreassen, CN ;
Gran, C ;
Lindegaard, JC .
SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (01) :62-72
[3]  
Anne PR, 2003, SEMIN ONCOL, V30, P417
[4]   Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy [J].
Bardet, E ;
Martin, L ;
Calais, G ;
Tuchais, C ;
Bourhis, J ;
Rhein, B ;
Feham, N ;
Alphonsi, M .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :57-60
[5]   Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial [J].
Bentzen, SM ;
Atasoy, BM ;
Daley, FM ;
Dische, S ;
Richman, PI ;
Saunders, MI ;
Trott, KR ;
Wilson, GD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5560-5567
[6]   Optimisation of conformal radiation therapy by intensity modulation: cancer of the larynx and salivary gland function [J].
Braaksma, MMJ ;
Wijers, OB ;
de Koste, JRV ;
van der Est, H ;
Schmitz, PIM ;
Nowak, PJCM ;
Levendag, PC .
RADIOTHERAPY AND ONCOLOGY, 2003, 66 (03) :291-302
[7]   Long-term parotid gland function after radiotherapy [J].
Braam, PM ;
Roesink, JM ;
Moerland, MA ;
Raaijmakers, CPJ ;
Schipper, M ;
Terhaard, CHJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (03) :659-664
[8]   Does amifostine have a role in chemoradiation treatment? [J].
Brizel, DM .
LANCET ONCOLOGY, 2003, 4 (06) :378-381
[9]   Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III study [J].
Buentzel, J ;
Micke, O ;
Adamietz, IA ;
Monnier, A ;
Glatzel, M ;
De Vries, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (03) :684-691
[10]   Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer [J].
Bussels, B ;
Maes, A ;
Hermans, R ;
Nuyts, S ;
Weltens, C ;
Van den Bogaert, W .
RADIOTHERAPY AND ONCOLOGY, 2004, 72 (02) :119-127